Azenta, Inc.

Azenta, Inc.

AZTANYSE / NASDAQHealthcareSmall cap

$44.80-$2.29 (-4.9%)

Last close · Data as of Nov 20, 2026

Market cap
$1.1B
P/E
-18.9x
EV / EBITDA
20.8x
Revenue
$593.8M
Net margin
-9.4%
ROCE
-1.2%

+49.3% over the last year

Azenta, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+25.4%
3M
+22.7%
6M
+141.2%
1Y
+49.3%
5Y
-62.5%

52-week range

Day change -$2.29 (-4.9%) from $47 to $45 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in AZTA, bought on each weekday since 2021.

News & filings

What Azenta filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 55.8 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 55.9% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments.

Read moreShow less

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Sector
Healthcare
Shares outstanding
45.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.1B
P/E
-18.9x
P/B
0.6x
EV / EBITDA
20.8x
EV / Sales
1.4x
P/S
1.8x
52-week high
$48.90
52-week low
$16.02

Profitability

Operating margin
-3.6%
Net margin
-9.4%
EBITDA margin
6.7%
ROE
-3.2%
ROCE
-1.2%
ROA
-2.7%
Asset turnover
0.29

Growth

Revenue
$593.8M
Revenue growth, 1Y
3.6%
Revenue CAGR, 3Y
2.2%
Net profit growth, 1Y
-66.2%
Free cash flow
$38.3M

Solvency

Current ratio
2.98
Debt / Equity
0.03
Debt / Assets
0.02
CFO / Net profit
-1.29
Cash / Market cap
26.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$593.8M
Cost of revenue$323.5M
Gross profit$270.3M
Operating expenses$292.0M
Research and development$30.4M
Selling, general and administrative$261.6M
Operating income-$21.7M
Interest and other$14.5M
Pretax income-$7.1M
Tax and other$48.6M
Net income-$55.8M

Revenue and net profit

Revenue grew 3.6% in FY2025; net profit is the dashed line.

Azenta, Inc. revenue and net profit by fiscal year
Azenta, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$555.5M$2.1B
FY2023$551.5M-$14.6M
FY2024$573.4M-$164.9M
FY2025$593.8M-$55.8M

Cash flows

FY2025: $72.2M from operations, $38.3M free after investment (dashed).

Azenta, Inc. operating and free cash flow by fiscal year
Azenta, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$466.0M-$543.5M
FY2023$5.8M-$33.6M
FY2024$49.7M$12.4M
FY2025$72.2M$38.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$593.8M+3.6%1Y
EBITDA
$39.5M-22.3%1Y
Net profit
-$55.8M
Cash from operations
$72.2M+45.1%1Y
Free cash flow
$38.3M+210.3%1Y
Revenue CAGR, 3Y
2.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$593.8M$39.5M-$55.8M$38.3M-3.2%+3.6%-66.2%

Monthly returns

Month-by-month returns of AZTA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.1B
Liabilities$332.6M
Equity$1.7B
Paid-in capital$529.6M
Retained earnings$1.4B
Treasury stock$201.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; AZTA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Azenta, Inc. (this company)1.4x

Not shown (no positive earnings and no EV / Sales): Savara Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Azenta, Inc.AZTAthis company$1.1B-18.9x0.6x-3.2%20.8x
Savara Inc.SVRA$1.1B-9.1x5.3x-58.5%-8.8x
Omada Health, Inc.OMDA$1.1B-84.7x4.7x-5.6%-181.0x
Xeris Biopharma Holdings, Inc.XERS$1.1B1916.5x77.6x4.0%28.6x
Collegium Pharmaceutical, Inc.COLL$1.1B16.9x3.5x20.8%4.1x
CONMED CorporationCNMD$1.1B22.5x1.0x4.6%10.5x
The Pennant Group, Inc.PNTG$1.0B35.4x3.1x8.9%24.4x
QuidelOrtho CorporationQDEL$1.0B-0.9x0.5x-58.9%-7.7x
EyePoint, Inc.EYPT$1.0B-4.4x3.4x-75.8%-4.1x
Peer median—8.0x3.4x-0.8%-0.0x

Year-to-date ROI

AZTA since 1 January, against earlier years.

Historical volatility

AZTA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Azenta, Inc. operating margin by fiscal year
Azenta, Inc. operating margin by fiscal year
DateOperating margin
FY2022-4.2%
FY2023-10.3%
FY2024-7.0%
FY2025-3.6%
LineFY2025
Cost of revenueCost Of Revenue$323.5M
Gross profitGross Profit$270.3M
Operating expensesOperating Expense$291.9M
Research and developmentResearch And Development$30.4M
Selling, general and administrativeSelling General And Administration$261.6M
Total expensesTotal Expenses$615.5M
Pretax incomePretax Income-$7.1M

Learn while you research

Academy chapters picked for Azenta, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →